BioLab Packing partners with Sino Biological, which has developed the world's first highly specific monoclonal antibody to the 2009 H1N1 virus. In 2012, Sino Biological has completed the preclinical development of Middle East respiratory syndrome coronavirus (MERS-CoV) neutralizing antibodies in 6 months. In 2013, it has completed the rapid development of H7N9 HA proteins in 12 days and the preclinical development of H7N9 neutralizing antibodies within 6 months. Furthermore, in order to help researchers combat ebola outbreak in 2014, Sino Biological has developed a series of reagents associated with ebola virus (EBOV), including recombinant proteins, antibodies, and genes for EBOV GP, NP, VP40 and VP24. Our virus research reagents focus on new outbreaks, the latest viral strains and vaccine strains, and hot viral molecules. Now, as the world's largest virus reagent center, Sino Biological offers approximately 3,000 genes, recombinant proteins, antibodies, ELISA kits, and cell lysates. These products can be applied to antiviral drug discovery, vaccine research, and diagnostics development for 20 important viruses, including influenza virus, human immunodeficiency virus (HIV), EBOV, coronavirus (CoV), respiratory syncytial virus (RSV), and cytomegalovirus (CMV) etc.
BioLab Packing partners with Sino Biological Inc., which has over 10 years' experience of recombinant protein research and development, we have more than 6000 recombinant proteins in stock, covering most hot research areas, such as immune checkpoints, antibody drug targets, CAR-T cell therapy targets, Fc receptors, influenza viral proteins and cytokines. Possessing high purity and validated bioactivity, Sino Biological recombinant proteins can support your scientific research from biopharmaceutical, protein structure, protein function, cell therapy to tool enzymes.
M13 is a filamentous bacteriophage composed of circular single stranded DNA (ssDNA) which is 647 nucleotides long encapsulated in approximately 27 copies of the major coat protein P8, and capped with 5 copies of two different minor coat proteins (P9, P6, P3) on the ends. Infection with filamentous phages is not lethal, however the infection causes turbid plaques in E. coli. It is a non-lytic virus. However a decrease in the rate of cell growth is seen in the infected cells. M13 plasmids are used for many recombinant DNA processes, and the virus has also been studied for its uses in nanostructures and nanotechnology. The phage coat is primarily assembled from a 5 amino acid protein called pVIII (or p8), which is encoded by gene VIII (or g8) in the phage genome. For a wild type M13 particle, it takes about approximately 27 copies of p8 to make the coat about 9 nm long. The coat's dimensions are flexible though and the number of p8 copies adjusts to accommodate the size of the single stranded genome it packages. The general stages to a viral life cycle are: infection, replication of the viral genome, assembly of new viral particles and then release of the progeny particles from the host. Filamentous phage use a bacterial structure known as the F pilus to infect E. coli, with the M13 p3 tip contacting the TolA protein on the bacterial pilus. The phage genome is then transferred to the cytoplasm of the bacterial cell where resident proteins convert the single stranded DNA genome to a double stranded replicative form.
Date: 30 October – 2 November 2017 Disciplines: Life Science, Health Science Location: Ishikawa (Kanazawa Station Kenrokuenguchi), Japan